Clinical Study on Expression of Tumor Abnormal Glycoproteins in Patients with Gastrointestinal Malignancies after Fluorouracil-based Chemotherapy
- Author:
Ni YIN
1
Author Information
- Publication Type:Journal Article
- Keywords: Colorectal cancer; Expression difference; Fluorouracil; Gastric cancer; Tumor abnormal glycoprotein (TAP)
- From: Chinese Pharmaceutical Journal 2019;54(24):2093-2096
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To acquire the expressing information about tumor abnormal glycoprotein (TAP) in the peripheral blood of the gastric cancer patients who are treated with fluorouracil and the colorectal cancer patients treated with fluorouracil, and to discuss the factors that affect its expression and its clinical significance. METHODS: This research was conducted on the basis of 99 gastric cancer patients and colorectal cancer patients whose diseases were pathologically diagnosed from May to December, 2018, including 53 gastric cancer patients treated with fluorouracil and paclitaxel and 46 colorectal cancer patients treated with fluorouracil and oxaliplatin. It tested their TAP values, collected the basic information, the type of the cancer, the stage of the cancer, serum tumor markers, etc. of the patients as well as analyzed the differences of the expression of TAP in gastrointestinal tumors with different characteristics. RESULTS: The expression value of TAP in the peripheral blood of the gastrointestinal cancer patients is (158.11±33.63), and the expression of TAP value has no statistical differences in the expression of different sexes, ages, types of the cancer, clinical stages and serum tumor markers. CONCLUSION: The fact that the expression of TAP has no differences in the gastrointestinal cancer patients with different characteristics can't be taken as the basis of identifying or diagnosing gastrointestinal tumors which are different in character.
